<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327859</url>
  </required_header>
  <id_info>
    <org_study_id>E2020-E044-318</org_study_id>
    <secondary_id>2004-003355-39</secondary_id>
    <nct_id>NCT01327859</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia</brief_title>
  <official_title>A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of donepezil&#xD;
      (Aricept) in Parkinson's Disease (PD) patients with dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete all 24 weeks of the double-blind study E2020-E044-316 (NCT00165815)&#xD;
      will be eligible for the open label extension study. Patients and caregiver/study partner&#xD;
      will need to provide additional written informed consent to participate in the open label&#xD;
      extension study. Safety and tolerability will be assessed after 4, 8 12, 24, 36 and 52 weeks.&#xD;
      Cognition, Global Clinical Function, Activities of Daily Living, and Behaviour will be&#xD;
      assessed after 24, and 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will primarily be assessed by recording of AEs</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of open-label donepezil (5-10 mg/day) on cognition (ADAS)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of open-label donepezil (5-10mg/day) on cognition(MMSE)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of open-label donepezil (5-10 mg/day) on Global Function (CIBIC)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of open-label donepezil (5-10 mg/day) on ADLs (DAD and Schwab and England scales)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of open-label donepezil (5-10 mg/day) on behavior (NPI)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Prior Donepezil 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Donepezil 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prior Donepezil 5mg</intervention_name>
    <description>Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.</description>
    <arm_group_label>Prior Donepezil 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prior Donzepezil 10mg</intervention_name>
    <description>Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.</description>
    <arm_group_label>Prior Donepezil 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prior Placebo</intervention_name>
    <description>Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.</description>
    <arm_group_label>Prior Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: patients must be aged 40 or over&#xD;
&#xD;
          -  Sex distribution: male and female&#xD;
&#xD;
          -  PD according to UK Brain Bank criteria 40 with good response to levodopa as judged by&#xD;
             investigator opinion.&#xD;
&#xD;
          -  Women of child bearing potential must have demonstrated a negative serum beta human&#xD;
             chorionic gonadotropin (B-HCG) at the screening visit for the double-blind study&#xD;
             (E2020-E044-316)(NCT00165815) and a negative urine test result at the screening visit&#xD;
             for the open label extension study, (E2020-E044-318)&#xD;
&#xD;
          -  Completed all 24 treatment weeks of the double-blind study E2020-E044-316&#xD;
             (NCT00165815)and completed assessments.&#xD;
&#xD;
          -  Outpatients, with a responsible and reliable caregiver/study partner&#xD;
&#xD;
          -  Health: generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane);&#xD;
             vision (glasses, contact lenses permissible), hearing (hearing aid permissible) and&#xD;
             speech sufficient for compliance with testing procedures; must be capable of&#xD;
             swallowing the study medication.&#xD;
&#xD;
          -  Written informed consent must be obtained from each patient and his/her&#xD;
             caregiver/study partner prior to subjecting the patient or caregiver/study partner to&#xD;
             any open label extension study related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating, women.&#xD;
&#xD;
          -  Women of childbearing potential unless:&#xD;
&#xD;
               -  surgically sterile or&#xD;
&#xD;
               -  must be practicing effective contraception (e.g. abstinence, IUD or barrier&#xD;
                  method plus hormonal method). These patients must be willing to remain on current&#xD;
                  form of contraception for the duration of the study, (post menopausal women must&#xD;
                  be amenorrheic for at least 12 months to be considered of non-child bearing&#xD;
                  potential).&#xD;
&#xD;
          -  Patients with evidence of other psychiatric/neurological disorders, i.e., stroke,&#xD;
             schizophrenia, seizure disorder, head injury with loss of consciousness (for at least&#xD;
             1 hour) within the past year, progressive supranuclear palsy, multisystem atrophy, or&#xD;
             dementia complicated by other organic disease.&#xD;
&#xD;
          -  Evidence of clinically significant, active gastrointestinal, renal, hepatic, endocrine&#xD;
             or cardiovascular system disease. Evidence of second or third degree heart block.&#xD;
             Patients with controlled hypertension (supine diastolic blood pressure (BP) &lt; 95&#xD;
             mmHg), right bundle branch block (complete or partial) and pacemakers may be included&#xD;
             in the study.&#xD;
&#xD;
          -  Patients previously treated with centrally active acetylchlinesterase (AChE)&#xD;
             inhibitors (e.g., physostigmine, tacrine, metrifonate, galantamine, rivastigmine,&#xD;
             donepezil) except the medication in the Aricept double-blind study E2020-E044-316&#xD;
             (NCT00165815).&#xD;
&#xD;
          -  Patients and/or caregivers/study partners who are unwilling or unable to fulfill the&#xD;
             requirements of the study.&#xD;
&#xD;
          -  Any condition which would make the patient or the caregiver/study partner, in the&#xD;
             opinion of the investigator, unsuitable for the study.&#xD;
&#xD;
          -  Patients with known hypersensitivity to AChE inhibitors.&#xD;
&#xD;
          -  Patients who were non-compliant with the inclusion/exclusion criteria or with the&#xD;
             study medication received in the preceding Aricept? double-blind study E2020-E044-316&#xD;
             (NCT00165815).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Harre</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <state>Canterbury</state>
        <zip>BA2 5RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Margaret Moline, PhD</name_title>
    <organization>Eisai Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

